Dr. Nasheed M. Hossain
Claim this profileLoyola University Medical Center
Studies Lymphoma
Studies Follicular Lymphoma
5 reported clinical trials
8 drugs studied
Area of expertise
1Lymphoma
13q positive
13q negative
12 positive
2Follicular Lymphoma
Affiliated Hospitals
Clinical Trials Nasheed M. Hossain is currently running
Post-CAR T-cell Therapy Drug Combo
for Non-Hodgkin's Lymphoma
This trial is testing two treatments, mosunetuzumab and polatuzumab vedotin, for patients with certain types of lymphoma that have come back or don't respond to other treatments. These treatments aim to stop cancer cells from growing or kill them directly. The goal is to see if these treatments can better control or shrink the cancer compared to not using them.
Recruiting1 award Phase 2
Venetoclax + Obinutuzumab
for Leukemia
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
Recruiting2 awards Phase 31 criteria
More about Nasheed M. Hossain
Clinical Trial Related5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Nasheed M. Hossain has experience with
- Obinutuzumab
- Venetoclax
- CD19 Chimeric Antigen Receptor (CAR) T Cells
- Bb2121
- Lenalidomide
- Ibrutinib
Breakdown of trials Nasheed M. Hossain has run
Lymphoma
Follicular Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nasheed M. Hossain specialize in?
Nasheed M. Hossain focuses on Lymphoma and Follicular Lymphoma. In particular, much of their work with Lymphoma has involved 13q positive patients, or patients who are 13q negative.
Is Nasheed M. Hossain currently recruiting for clinical trials?
Yes, Nasheed M. Hossain is currently recruiting for 2 clinical trials in Maywood Illinois. If you're interested in participating, you should apply.
Are there any treatments that Nasheed M. Hossain has studied deeply?
Yes, Nasheed M. Hossain has studied treatments such as Obinutuzumab, Venetoclax, CD19 Chimeric Antigen Receptor (CAR) T Cells.
What is the best way to schedule an appointment with Nasheed M. Hossain?
Apply for one of the trials that Nasheed M. Hossain is conducting.
What is the office address of Nasheed M. Hossain?
The office of Nasheed M. Hossain is located at: Loyola University Medical Center, Maywood, Illinois 60153 United States. This is the address for their practice at the Loyola University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.